In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Allergan plc

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

Financing Deals

Finance Watch: Have Investors Reached IPO Fatigue?

Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.

Financing Growth

Revance Builds Therapeutics Credibility For DaxibotulinumtoxinA Ahead Of Aesthetics Launch

The long-acting neuromodulator improved symptoms of cervical dystonia in a Phase III trial with longer duration of efficacy versus older products; a launch for aesthetics is expected soon.  

Clinical Trials Business Strategies

BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis

Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response. 

Clinical Trials Gastrointestinal
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Actavis, Inc.
    • Actavis plc
    • Akarna Therapeutics Ltd.
    • Allergan, Inc.
    • Anterios, Inc.
    • Arrow Group (Subsidiaries: Arrow Generics (U.K), Cobalt Group (U.S.))
    • AqueSys, Inc.
    • Bonti, Inc.
    • Chase Pharmaceuticals Corporation, Inc.
    • Durata Therapeutics
    • Elastagen Pty Ltd
    • EndoArt SA
    • Envy Medical, Inc.
    • Forest Laboratories [Aptalis Pharmaceutical Technologies
    • (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.]
    • Furiex Pharmaceuticals, Inc. (PPD, Inc.)
    • Kythera Biopharmaceuticals, Inc.
    • MAP Pharmaceuticals
    • Motus Therapeutics, Inc. (Rhythm Health, Inc.)
    • Naurex, Inc.
    • Oculeve
    • Regado Biosciences, Inc.
    • RetroSense Therapeutics, LLC
    • Silom Medical Company
    • Uteron Pharma SA
    • Warner Chilcott PLC (Galen Holdings PLC)
    • Watson Pharmaceuticals, Inc.
    • Tobira Therapeutics, Inc.
    • Topokine Therapeutics
    • Vitae Pharmaceuticals, Inc.
    • ForSight VISION5, Inc.
    • LifeCell Corporation
    • ZELTIQ Aesthetics, Inc.
    • Zonagen, Inc.
    • Repros Therapeutics, Inc.
UsernamePublicRestriction

Register